Dec. 6, 2016
BioAtla LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, announced on December 6, 2016 that together with Beijing Sinobioway Group Company, Limited, they have selected the first four CAB product programs for development. The specific program candidates and the targeted indications were not disclosed. As a result, BioAtla received on November 1, 2016 a $36 million payment from Sinobioway. Including these funds, BioAtla has received more than $100 million in program payments and equity investments relating to its strategic collaboration agreement with Sinobioway.